These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19171928)

  • 1. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.
    Flint OP; Noor MA; Hruz PW; Hylemon PB; Yarasheski K; Kotler DP; Parker RA; Bellamine A
    Toxicol Pathol; 2009 Jan; 37(1):65-77. PubMed ID: 19171928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.
    Noor MA
    Curr HIV/AIDS Rep; 2007 Aug; 4(3):126-34. PubMed ID: 17883998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV protease inhibitors and obesity.
    Anuurad E; Bremer A; Berglund L
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):478-85. PubMed ID: 20717021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A characterisation of low-grade inflammation and metabolic complications in HIV-infected patients.
    Andersen O
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipid disorders in patients with HIV-induced diseases].
    Chanu B; Valensi P
    Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment.
    Giralt M; Díaz-Delfín J; Gallego-Escuredo JM; Villarroya J; Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3371-8. PubMed ID: 20687888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance in HIV-related lipodystrophy.
    Mikhail N
    Curr Hypertens Rep; 2003 Apr; 5(2):117-21. PubMed ID: 12642010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic metabolic syndrome associated with HAART.
    Haugaard SB
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):429-45. PubMed ID: 16863444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations.
    Caron-Debarle M; Boccara F; Lagathu C; Antoine B; Cervera P; Bastard JP; Vigouroux C; Capeau J
    Curr Pharm Des; 2010 Oct; 16(30):3352-60. PubMed ID: 20687886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
    AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients.
    Stankov MV; Behrens GM
    Curr Pharm Des; 2010 Oct; 16(30):3361-71. PubMed ID: 20687889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
    Kolter DP
    AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
    Lagathu C; Bastard JP; Auclair M; Maachi M; Kornprobst M; Capeau J; Caron M
    Antivir Ther; 2004 Dec; 9(6):911-20. PubMed ID: 15651750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.
    Bastard JP; Caron M; Vidal H; Jan V; Auclair M; Vigouroux C; Luboinski J; Laville M; Maachi M; Girard PM; Rozenbaum W; Levan P; Capeau J
    Lancet; 2002 Mar; 359(9311):1026-31. PubMed ID: 11937183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.
    Willig AL; Overton ET
    Curr HIV/AIDS Rep; 2016 Oct; 13(5):289-96. PubMed ID: 27541600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
    Barbaro G
    Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
    Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
    Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy.
    Murata H; Hruz PW; Mueckler M
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):1-8. PubMed ID: 12462148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.